Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | OGT | O15294 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12315754 | 0.95 | ALDH1A1 (0.34) | AKT1OGTROCK2CYP3A4 | |
| SCHEMBL2488582 | 0.88 | PDGFRB (0.32) | DPP8DPP7AKT1PAK1HCRTR2 | |
| Trifluoroacetic Acid SCHEMBL2511751 | 0.86 | HAT1 (0.40) | CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL2487274 | 0.86 | SMYD2 (0.32) | DPP8DPP7ROCK2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL2487366 | 0.85 | ROCK2 (0.46) | DPP8DPP7AKT1DPP4ROCK2 | |
| SCHEMBL2490206 | 0.85 | HCRTR2 (0.40) | AKT1HCRTR2 | |
| SCHEMBL2485351 | 0.85 | ALDH1A1 (0.36) | HCRTR2ROCK2 | |
| Trifluoroacetic Acid SCHEMBL2488017 | 0.84 | DPP8 (0.34) | DPP8DPP7HCRTR2ABHD6DPP4 | |
| SCHEMBL2805666 | 0.82 | SMYD2 (0.41) | CYP3A4 | |
| SCHEMBL12315752 | 0.80 | HAT1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263610-B2 | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds | ARQULE, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2379551-A1 | SUBSTITUTED PYRAZOLO [3, 4-B]PYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100239526-A1 | SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010078427-A1 | SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239526-A1 | SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS | NQO1, IDH3B, IDH1 | DPP8 2980/4885DPP7 1996/4885AKT1 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.